MX2015003642A - Cmpf como biomarcador para diabetes y metodos asociados. - Google Patents

Cmpf como biomarcador para diabetes y metodos asociados.

Info

Publication number
MX2015003642A
MX2015003642A MX2015003642A MX2015003642A MX2015003642A MX 2015003642 A MX2015003642 A MX 2015003642A MX 2015003642 A MX2015003642 A MX 2015003642A MX 2015003642 A MX2015003642 A MX 2015003642A MX 2015003642 A MX2015003642 A MX 2015003642A
Authority
MX
Mexico
Prior art keywords
cmpf
methods
impaired glucose
glucose homeostasis
cell dysfunction
Prior art date
Application number
MX2015003642A
Other languages
English (en)
Inventor
Michael Wheeler
Kacey Prentice
Feihan Dai
Ravi Retnakaran
Original Assignee
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toronto filed Critical Univ Toronto
Publication of MX2015003642A publication Critical patent/MX2015003642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen métodos para identificar o monitorear a una persona que tenga o esté en riesgo de desarrollar una homeostasis deficiente de la glucosa. Se muestra que el ácido carboxi-4-meti-5-propil-2-furanpropanóico (CMPPF) es un biomarcador para la homeostasis deficiente de la glucosa y/o las condiciones caracterizadas por malfuncionamiento de las células ß. Comparar un nivel de prueba de CMPF en un sujeto a un nivel de control identifica a sujetos que tienen o están en riesgo de desarrollar una homeostasis deficiente de la glucosa. También se proveen métodos para causar homeostasis deficiente de la glucosa o malfuncionamiento de las células ß y métodos para detectar los compuestos que afectan la actividad de las células ß. También se proveen métodos para el tratamiento deI malfuncionamiento de la célula ß al reducir los niveles fisiológicos de CMPF en un sujeto así como el uso de un modulador OAT para el tratamiento del malfuncionamiento de la celda ß.
MX2015003642A 2012-09-21 2013-09-20 Cmpf como biomarcador para diabetes y metodos asociados. MX2015003642A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261703867P 2012-09-21 2012-09-21
US201361787718P 2013-03-15 2013-03-15
PCT/CA2013/000798 WO2014043793A1 (en) 2012-09-21 2013-09-20 Cmpf as a biomarker for diabetes and associated methods

Publications (1)

Publication Number Publication Date
MX2015003642A true MX2015003642A (es) 2016-07-11

Family

ID=50340483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003642A MX2015003642A (es) 2012-09-21 2013-09-20 Cmpf como biomarcador para diabetes y metodos asociados.

Country Status (8)

Country Link
US (1) US9726659B2 (es)
EP (1) EP2897614A4 (es)
CN (1) CN104822378A (es)
BR (1) BR112015006284A2 (es)
CA (1) CA2885416A1 (es)
IN (1) IN2015DN02868A (es)
MX (1) MX2015003642A (es)
WO (1) WO2014043793A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2917483A1 (en) 2013-07-09 2015-01-15 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
CN104678016B (zh) * 2015-02-11 2017-05-03 浙江中烟工业有限责任公司 一种采用高效液相色谱测定苯并芘在吸烟后大鼠肺部沉积量的方法
US20180028100A1 (en) * 2015-02-11 2018-02-01 Siemens Aktiengesellschaft System and non-invasive method for examining at least parts of blood fractions, and use of the system
WO2016145532A1 (en) * 2015-03-16 2016-09-22 The Governing Council Of The University Of Toronto Cmpf for the treatment or prevention of hepatic steatosis
WO2018042072A1 (en) * 2016-09-02 2018-03-08 Afekta Technologies Oy Furan fatty acid biomarkers of nutritional status
CN109765360B (zh) * 2018-12-12 2020-01-21 杭州博谱医药科技有限公司 Cmpf均相酶免疫检测试剂盒、制备方法及检测方法
CN110007092A (zh) * 2019-04-08 2019-07-12 杭州博谱医药科技有限公司 一种胶乳微球-蛋白-cmpf偶联物及其制备方法以及测定血清中cmpf含量的试剂盒
CN110187123B (zh) * 2019-05-06 2022-07-22 天津医科大学总医院 一种糖尿病早期诊断生物标志物及其应用
CN114924011B (zh) * 2022-06-30 2023-08-25 重庆大学附属肿瘤医院 高效液相色谱串联质谱法检测血浆中cmpf含量的方法
EP4385508A1 (en) * 2022-12-16 2024-06-19 Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD) Furan fatty acids for enhancing muscle mass

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227689B1 (en) 2007-11-02 2012-12-26 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
WO2010045180A1 (en) 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
US8206591B2 (en) * 2008-10-16 2012-06-26 Fresenius Medical Care Holdings, Inc. Method of removing protein-bound deleterious substances during extracorporeal renal replacement treatment
US8980548B2 (en) 2010-05-19 2015-03-17 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
CA2807811A1 (en) 2010-07-28 2012-02-02 Metabolon Inc. Biomarkers for prostate cancer and methods using the same
US20140303228A1 (en) 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
AU2012347557A1 (en) 2011-12-09 2014-07-03 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same

Also Published As

Publication number Publication date
IN2015DN02868A (es) 2015-09-11
EP2897614A1 (en) 2015-07-29
US9726659B2 (en) 2017-08-08
US20150247839A1 (en) 2015-09-03
CA2885416A1 (en) 2014-03-27
WO2014043793A1 (en) 2014-03-27
CN104822378A (zh) 2015-08-05
BR112015006284A2 (pt) 2017-07-04
EP2897614A4 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
MX2015003642A (es) Cmpf como biomarcador para diabetes y metodos asociados.
WO2016094904A8 (en) Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
MX2020006720A (es) Beta-caseina a2 y niveles de glucosa en sangre.
MX2014000537A (es) Metodo para evaluar la condicion de la piel y/o cuero cabelludo.
IN2014DN08537A (es)
NZ729773A (en) Biomarkers for disease progression in melanoma
AU2012313353A8 (en) Screening method
WO2014047442A3 (en) Biomarkers for assessing treatment of sialic acid deficiency diseases and conditions
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
WO2012024302A3 (en) Biomarkers of cancer
RU2011116505A (ru) Способ диагностики различных форм острого пиелонефрита
EA201001297A1 (ru) Способ диагностики меланомы человека на основании определения уровня экспрессии гена phf10, диагностический набор
BR112012026314A2 (pt) biomarcador para função renal em pacientes com diabetes do tipo 2
EA201690217A1 (ru) Способ и диагностический набор для контроля рассеянного склероза (pc)
UA75293U (ru) Способ прогнозирования риска возникновения острых нарушений мозгового кровообращения у больных с сахарным диабетом
UA92113U (uk) Спосіб прогнозування розвитку цукрового діабету 2 типу у хворих на гіпертонічну хворобу за активністю апеліну
LV14437A (lv) Sirds asinsvadu patoloģijas efektīvas ārstešanas noteikšanas paņēmiens gados vecākiem cilvēkiem ar 2. tipa cukura diabētu
UA87716U (uk) Спосіб прогнозування функціональних і структурних змін у сітківці хворих непроліферативною діабетичною ретинопатією